Methods of treating restenosis

• US 7,291,604 B2
• Filed: 09/03/2004
• Issued: 11/06/2007
• Est. Priority Date: 09/03/2003
• Status: Expired due to Fees

• Current Assignee: Institut National De La Sante Et De La Recherche Medicale (Inserm) (Allianz Global Investors GmbH), The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Del Monte, Federica, Lompr, Anne-Marie, Lipskaia, Larissa, Hajjar, Roger J.
• Primary Examiner(s): Wehbe′; Anne M.
• Assistant Examiner(s): SAJJADI, FEREYDOUN GHOTB
• Application Number:
  US10/933,807
• Publication Number:
  US 20050112101A1
• Time in Patent Office: 1,159 Days
• Field of Search: 514/44, 435/320.1
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• CPC Class Codes: A61L 33/128 Other specific proteins or polypeptides not covered by A61L33/122 - A61L33/126
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 9/14 Hydrolases (3)
• CPC Class Codes: C12Y 306/03008 Ca2+-transporting ATPase (3.6.3.8)

Abstract

Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel.

Claims

1. A method of reducing restenosis in a subject following angioplasty, the method comprising directly administering to the injured blood vessel of said subject a nucleic acid that encodes a SERCA2a polypeptide, wherein the nucleic acid is a component of an adenovirus-based vector, thereby reducing restenosis.

2. The method of claim 1, wherein the nucleic acid encodes SERCA2a operably linked to a viral promoter.

3. The method of claim 1, wherein the nucleic acid encodes SERCA2a operably linked to an inducible promoter.

4. The method of claim 1, wherein the nucleic acid is administered in an amount effective to reduce neointimal hyperplasia.

5. A method of reducing restenosis in a subject folloeing angioplasty, the method comprising directly administering to the injured blood vessel of said subject a nucleic acid that encodes a SERCA2a polypeptide, wherein the nucleic acid is a component of an adeno-associated virus-based vector, thereby reducing restenosis,

6. The method of claim 5, wherein the nucleic acid encodes SERCA2a operably linked to a viral promoter.

7. The method of claim 5, wherein the nucleic acid encodes SERCA2a operably linked to an inducible promoter.

8. The method of claim 5, wherein the nucleic acid is administered in an amount effective to reduce neointimal hyperplasia.